R H Rimawi1, A Frenkel, P P Cook. 1. Division of Infectious Diseases, East Carolina University - Brody School of Medicine, Greenville, NC 27834, USA. RamzyRimawi@hotmail.com
Abstract
WHAT IS KNOWN AND OBJECTIVE: The US Food and Drug Administration approved ceftaroline in 2010 for the treatment of community-acquired pneumonia and skin and soft-tissue infections. The most common adverse reactions are diarrhoea, nausea and rash. To present the first case of neutropenia directly related to ceftaroline. CASE SUMMARY: A 90-year-old female was given ceftaroline for treatment of a pneumonia complicated by methicillin-resistant Staphylococcus aureus bacteraemia and possible vertebral osteomyelitis. After 25 days of ceftaroline, she developed neutropenia. Ceftaroline was discontinued and her white blood cell count returned to normal within one week. WHAT IS NEW AND CONCLUSION: Although neutropenia is a potential cephalosporin class effect, we present the first case of neutropenia directly related to ceftaroline. Agranulocytosis and neutropenia are rare, yet potentially life-threatening adverse effects of cephalosporins. Healthcare providers should be aware of the potential for ceftaroline to cause neutropenia, particularly in patients treated for greater than two weeks.
WHAT IS KNOWN AND OBJECTIVE: The US Food and Drug Administration approved ceftaroline in 2010 for the treatment of community-acquired pneumonia and skin and soft-tissue infections. The most common adverse reactions are diarrhoea, nausea and rash. To present the first case of neutropenia directly related to ceftaroline. CASE SUMMARY: A 90-year-old female was given ceftaroline for treatment of a pneumonia complicated by methicillin-resistant Staphylococcus aureus bacteraemia and possible vertebral osteomyelitis. After 25 days of ceftaroline, she developed neutropenia. Ceftaroline was discontinued and her white blood cell count returned to normal within one week. WHAT IS NEW AND CONCLUSION: Although neutropenia is a potential cephalosporin class effect, we present the first case of neutropenia directly related to ceftaroline. Agranulocytosis and neutropenia are rare, yet potentially life-threatening adverse effects of cephalosporins. Healthcare providers should be aware of the potential for ceftaroline to cause neutropenia, particularly in patients treated for greater than two weeks.
Authors: Kimberly G Blumenthal; James L Kuhlen; Ana A Weil; Christy A Varughese; David W Kubiak; Aleena Banerji; Erica S Shenoy Journal: J Allergy Clin Immunol Pract Date: 2016-04-27
Authors: Katherine W LaVie; Scott W Anderson; Hollis R O'Neal; Todd W Rice; Tatiana C Saavedra; Catherine S O'Neal Journal: Antimicrob Agents Chemother Date: 2015-10-26 Impact factor: 5.191
Authors: Vidya P Narayanaswamy; Scott A Giatpaiboon; John Uhrig; Paul Orwin; William Wiesmann; Shenda M Baker; Stacy M Townsend Journal: PLoS One Date: 2018-01-17 Impact factor: 3.240